Trastuzumab Botidotin Prolongs PFS vs T-DM1 in HER2+ Advanced Breast CancerByCancer Network StaffSeptember 15th 2026
Camizestrant Combo Misses PFS End Point in First-Line ER+/HER2– Breast CancerByCancer Network StaffSeptember 14th 2026
Early Camizestrant Switching Has a Learning Curve Before Becoming StandardByErica L. Mayer, MD, MPHSeptember 11th 2026
Early Camizestrant Is Favored Upon ESR1 Mutation Emergence in Breast CancerByErica L. Mayer, MD, MPHSeptember 10th 2026
Toxicity Management of PI3K Pathway Inhibitors in HR+/HER2− mBCBySeth Wander, MD, PhD,Erica L. Mayer, MD, MPH,Kathryn Post, PhD, RN, ANP-BC,Jennifer Hutchinson, PharmD, BCOPSeptember 10th 2026